Orion Pharma in the news
Pharmaceuticals oncology pain treatment
Tamtam found 5 recent articles about Orion Pharma.
- Orion updates time estimate for the potential related to the annual Nubeqa® net sales recorded by Orion
Orion expects its Nubeqa® product to exceed EUR 1 billion in annual net sales by the end of the decade, though timing is uncertain due to market and regulatory factors.
- Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
BlackRock decreased its stake in Orion Corporation below 5%, a Nordic pharma company specializing in oncology and pain with EUR 1.5 billion sales in 2024.
- 'Cambridge our Silicon Valley' says Orion Pharma as it unveils key opportunities
Orion Pharma is expanding its biologics R&D in Cambridge, UK, recruiting top talent to complement its Finnish operations and support long-term innovation.
- Orion Obtains Exclusive Commercial License for Abzena’s Antibody
Orion licensed a monoclonal antibody from Abzena to enhance its oncology drug development pipeline targeting a cancer with high unmet need.
- Orion Corporation to open Biologics R & D centre in Cambridge
Orion is establishing a new biologics R&D centre in Cambridge, expanding its focus on biological therapies while reorganizing some Finnish R&D roles.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Orion Pharma?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies